Ab­b­Vie drops Cy­tomX part­ner­ship, leav­ing PhII pro­gram in the air

Ab­b­Vie is wind­ing down its col­lab­o­ra­tion with Cy­tomX sev­en years af­ter first em­bark­ing on a search for con­di­tion­al­ly ac­ti­vat­ed can­cer im­munother­a­py pro­grams.

Cy­tomX will be weigh­ing its op­tions for CX-2029, a CD71-di­rect­ed an­ti­body-drug con­ju­gate, af­ter Ab­b­Vie de­cid­ed not to ad­vance the drug in­to ad­di­tion­al stud­ies, the biotech dis­closed in its quar­ter­ly up­date. The Big Phar­ma part­ner al­so served no­tice to ter­mi­nate their li­cens­ing deal, which dates back to 2016, on the same day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER